Business steps in: Companies also take into account the potential of plasma.
Adam Schechter, CEO of research firm LabCorp, said at a Red Cross roundtable that his company would offer to test antibodies for free through doctors’ offices to increase blood donors. “LabCorp is currently working with health authorities and the community of service providers on detailed information about the three-month program and will provide additional information in the near future,” the company said in a statement.
Paul Perrault, CEO of CSL Limited, said his company and the NIH are developing projects a clinical trial to test a treatment known as hyperimmune globulin, which is derived from convalescent plasma. The company is recruiting patients for testing next month. If he shows that the treatment is effective, CSL can apply to the FDA by the end of this year, Perrault said.
What̵7;s next: Gan said the agency is reviewing the data underlying the effectiveness of convalescent plasma. Clinical trials are ongoing, and emergency FDA approval for expanded plasma use may soon be available.